666 related articles for article (PubMed ID: 29467275)
1. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in
Hirano T; Yasuda H; Hamamoto J; Nukaga S; Masuzawa K; Kawada I; Naoki K; Niimi T; Mimasu S; Sakagami H; Soejima K; Betsuyaku T
Mol Cancer Ther; 2018 Apr; 17(4):740-750. PubMed ID: 29467275
[TBL] [Abstract][Full Text] [Related]
2. Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
Tanaka H; Sakagami H; Kaneko N; Konagai S; Yamamoto H; Matsuya T; Yuri M; Yamanaka Y; Mori M; Takeuchi M; Koshio H; Hirano M; Kuromitsu S
Mol Cancer Ther; 2019 Aug; 18(8):1366-1373. PubMed ID: 31092564
[TBL] [Abstract][Full Text] [Related]
3. MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib.
Ninomiya K; Ohashi K; Makimoto G; Tomida S; Higo H; Kayatani H; Ninomiya T; Kubo T; Ichihara E; Hotta K; Tabata M; Maeda Y; Kiura K
Sci Rep; 2018 Jan; 8(1):1955. PubMed ID: 29386539
[TBL] [Abstract][Full Text] [Related]
4. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
5. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.
Hirano T; Yasuda H; Tani T; Hamamoto J; Oashi A; Ishioka K; Arai D; Nukaga S; Miyawaki M; Kawada I; Naoki K; Costa DB; Kobayashi SS; Betsuyaku T; Soejima K
Oncotarget; 2015 Nov; 6(36):38789-803. PubMed ID: 26515464
[TBL] [Abstract][Full Text] [Related]
6. LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo.
Liu Y; Lai M; Li S; Wang Y; Feng F; Zhang T; Tong L; Zhang M; Chen H; Chen Y; Song P; Li Y; Bai G; Ning Y; Tang H; Fang Y; Chen Y; Lu X; Geng M; Ding K; Yu K; Xie H; Ding J
Cancer Sci; 2022 Feb; 113(2):709-720. PubMed ID: 34855271
[TBL] [Abstract][Full Text] [Related]
7. ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Azuma K; Nishio M; Hayashi H; Kiura K; Satouchi M; Sugawara S; Hida T; Iwamoto Y; Inoue A; Takeda K; Ikeda S; Nakagawa T; Takeda K; Asahina S; Komatsu K; Morita S; Fukuoka M; Nakagawa K
Cancer Sci; 2018 Aug; 109(8):2532-2538. PubMed ID: 29807396
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.
Hasegawa H; Yasuda H; Hamamoto J; Masuzawa K; Tani T; Nukaga S; Hirano T; Kobayashi K; Manabe T; Terai H; Ikemura S; Kawada I; Naoki K; Soejima K
Lung Cancer; 2019 Jan; 127():146-152. PubMed ID: 30642543
[TBL] [Abstract][Full Text] [Related]
9. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Yasuda H; Park E; Yun CH; Sng NJ; Lucena-Araujo AR; Yeo WL; Huberman MS; Cohen DW; Nakayama S; Ishioka K; Yamaguchi N; Hanna M; Oxnard GR; Lathan CS; Moran T; Sequist LV; Chaft JE; Riely GJ; Arcila ME; Soo RA; Meyerson M; Eck MJ; Kobayashi SS; Costa DB
Sci Transl Med; 2013 Dec; 5(216):216ra177. PubMed ID: 24353160
[TBL] [Abstract][Full Text] [Related]
10. EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors.
Shaffer W; Kobayashi IS; Sentana-Lledo D; Sundararaman S; Lee MD; Rangachari D; VanderLaan PA; Kobayashi SS; Costa DB
Lung Cancer; 2023 Jul; 181():107250. PubMed ID: 37196448
[TBL] [Abstract][Full Text] [Related]
11. Targeting EGFR
Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.
Gao X; Le X; Costa DB
Expert Rev Anticancer Ther; 2016; 16(4):383-90. PubMed ID: 26943236
[TBL] [Abstract][Full Text] [Related]
13. Osimertinib Induces the Opposite Effect of Proliferation and Migration in the Drug Resistance of EGFR-T790M Non-small Cell Lung Cancer Cells.
Wang RH; Chang CJ; Chen CH; Liu KK; Chao JI
Anticancer Agents Med Chem; 2023; 23(11):1309-1319. PubMed ID: 36815658
[TBL] [Abstract][Full Text] [Related]
14. Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report.
Chen ZW; Lin G; Shih HJ; Wu CE
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614045
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
16. T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-Small Cell Lung Cancer.
Watanabe S; Yoshida T; Kawakami H; Takegawa N; Tanizaki J; Hayashi H; Takeda M; Yonesaka K; Tsurutani J; Nakagawa K
Mol Cancer Ther; 2017 Nov; 16(11):2563-2571. PubMed ID: 28839001
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations.
McCoach CE; Jimeno A
Drugs Today (Barc); 2016 Oct; 52(10):561-568. PubMed ID: 27910964
[TBL] [Abstract][Full Text] [Related]
18. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
Lung Cancer; 2017 Jun; 108():228-231. PubMed ID: 28625641
[TBL] [Abstract][Full Text] [Related]
19. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
Zhang YC; Chen ZH; Zhang XC; Xu CR; Yan HH; Xie Z; Chuai SK; Ye JY; Han-Zhang H; Zhang Z; Bai XY; Su J; Gan B; Yang JJ; Li WF; Tang W; Luo FR; Xu X; Wu YL; Zhou Q
EBioMedicine; 2019 May; 43():180-187. PubMed ID: 31027916
[TBL] [Abstract][Full Text] [Related]
20. Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.
Wei B; Zhao C; Li J; Zhao J; Ren P; Yang K; Yan C; Sun R; Ma J; Guo Y
Mol Oncol; 2019 May; 13(5):1226-1234. PubMed ID: 30927306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]